Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

And other biotech news brought to you by The Readout.

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.